OncoTwin and Genomic Testing (4baseCare)

4baseCare is a Bengaluru-based precision oncology company that combines genomic testing with AI to personalize cancer care. It operates a multi-country lab network and the Global Cancer Diversity Atlas, which the site reports at over 30,000 genomic profiles across 15+ countries.

Its OncoTwin AI platform supports patient twin matching, molecular tumor board decisions, clinical trial optimization and real-world evidence for biomarker and drug discovery. Tests include tissue and liquid profiling, HRD testing and germline cancer risk testing. Infosys and Illumina are listed as backers.

• Tissue and liquid profiling: solid tumor DNA/RNA and ctDNA tests.
• SoLiQ: dual-source tissue, liquid and germline testing.
• HRD testing: PARPredict test for homologous recombination deficiency.
• OncoTwin: AI platform for twin matching and tumor board support.
• Global Cancer Diversity Atlas: genomic reference dataset across 70+ cancer types.
• Germline risk testing: inherited cancer risk assessment.

Vietnamese cancer hospitals could partner on genomic profiling labs. Pharma sponsors could use real-world genomic data for trial recruitment.

• Genomic profiling tailored to diverse populations through the cancer diversity atlas.
• AI decision support for molecular tumor boards.
• Clinical trial matching and optimization for pharma partners.
• Hospital-linked lab model with regional expansion plans.

Precision oncology demand is rising in Asia, where reference genomic data often under-represents local populations. Vietnam has growing cancer care needs and could benefit from hospital-linked genomics labs; 4baseCare names Southeast Asia in its expansion plans.

Bengaluru, India. Series B first close of Rs 90 crore in Jan 2026, total Rs 128 crore in Jun 2026 co-led by Ashish Kacholia and Lashit Sanghvi; Infosys and Yali Capital are investors. Entrepreneur of the Year, BioSpectrum India Excellence Awards 2025.